AB Science SA (Euronext - FR0010557264 - AB) announces that its stock continues to be covered by Maxim Group, an independent US-based full-service investment bank, securities and wealth management ...

Operating income consists exclusively of revenue from the marketing of a veterinary medicine. Revenue is up 10% compared with 31 December 2024 and stands at €1,174 thousand as of 31 December 2025, ...

AB Science has received a binding offer for a Clinical Trial Funding Insurance policy from Medical & Commercial International Ltd. (MCI), Lloyd’s Syndicate 1902, for its Phase III clinical trial ...

The average one-year price target for AB Science (ENXTPA:AB) has been revised to €4.31 / share. This is an increase of 22.25% from the prior estimate of €3.53 dated September 27, 2025. The price ...

AB Science SA (Euronext - FR0010557264 - AB) today announced that it has filed an application for conditional Marketing Authorization to the European Medicines Agency (EMA) for Alsitek (masitinib) in ...

a 24-month capital grace period from the opening date of the first conciliation procedure in favour of AB Science, i.e. January 17, 2025, with resumption of amortisation from January 31, 2027 for ...

While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are ...

AB Science SA (Euronext - FR0010557264 - AB) today announces the postponement of its annual general shareholders’ meeting. In the exceptional context of the Covid-19 pandemic and in accordance with ...